Michigan Administrative Code › Department - Licensing and Regulatory Affairs › Bureau of Professional Licensing › Board of Optometry › Board of Optometry - General Rules › Part 1 - GENERAL PROVISIONS › Section R. 338.301 - Definitions

Current through Vol. 24-12, July 15, 2024
Rule 1.
(1) As
					 used in these rules:
(a) "AAO" means the
					 American Academy of Optometry.
(b)
					 "ACOE" means the Accreditation Council on Optometric Education.
(c) "Adverse drug reaction" means an adverse
					 physical or psychological reaction experienced by an individual resulting from
					 a diagnostic therapeutic agent administered by an optometrist that occurs
					 within 24 hours after the therapeutic agent was administered. An adverse drug
					 reaction includes any of the following:
(i)
					 Red eye.
(ii) Painful
					 eye.
(iii) Decrease in
					 vision.
(iv) Pale or red swelling
					 of the periocular or periorbital tissues.
(v) Nausea.
(vi) Vomiting.
(vii) Fainting.
(viii) Mental confusion.
(ix) Cessation of
					 respiration.
(d) "AOA"
					 means the American Optometric Association.
(e) "Board" means the Michigan board of
					 optometry.
(f) "Classroom hour,"
					 for the purpose of determining whether a course of study meets the requirements
					 of section
					 17412(2)(a) or
					 17435(2)(b) of
					 the code, MCL
					 333.17412 and
					 333.17435, means a 50 to 60
					 minute period of lecture, group discussion, or laboratory directly associated
					 with a course in pharmacology. Time spent working in a clinic other than as
					 part of a laboratory directly associated with a course in pharmacology does not
					 qualify as a "classroom hour."
(g)
					 "Code" means the public health code, 1978 PA 368, MCL
					 333.1101 to
					 333.25211.
(h) "COPE" means the Council on Optometric
					 Practitioner Education.
(i) "Course
					 of study in general and clinical pharmacology" means a course of study that is
					 completed in a board-approved school or college, in general and clinical
					 pharmacology as it relates to optometry, with the characteristics described in
					 section
					 17412(2)(a) of
					 the code, MCL
					 333.17412. Not less than 30 of
					 the 60 classroom hours of the course of study must be allocated to ocular
					 pharmacology and must emphasize the systemic effects of, and reactions to,
					 topical ocular diagnostic pharmaceutical agents, including the emergency
					 management and referral of any adverse reactions that may occur.
(j) "Course of study relating to the didactic
					 and clinical use of therapeutic pharmaceutical agents" means a course of study
					 that is comprised of a minimum of 10 quarter hours or 7 semester hours of
					 credit or 100 classroom hours of study, is completed in a board-approved school
					 or college, and is in subjects relating to the didactic and clinical use of
					 therapeutic pharmaceutical agents related to optometry.
(k) "CPDO" means the Continued Professional
					 Development in Optometry.
(l) "CPR"
					 means cardiopulmonary resuscitation.
(m) "Department" means the department of
					 licensing and regulatory affairs.
(n) "Established patient" means an individual
					 who has received a professional service from a provider within the
					 optometrist's practice group within the preceding 3 years and 1 day.
(o) "Informed consent for an established
					 patient" means consent by a patient or a patient's legal representative for
					 treatment, medication, or services after there has been full disclosure of the
					 facts needed for the patient or the patient's legal representative to make a
					 voluntary decision based on the elements of knowledge, comprehension, and
					 willingness to receive the treatment, medication, or service.
(p) "Informed consent for a new patient"
					 means a written agreement or documentation of a verbal agreement by a patient
					 or a patient's legal representative for treatment, medication, or services
					 after there has been full disclosure of the facts needed for the patient or the
					 patient's legal representative to make a voluntary decision based on the
					 elements of knowledge, comprehension, and willingness to receive the treatment,
					 medication, or service.
(q) "MOA"
					 means the Michigan Optometric Association.
(r) "NBEO" means the National Board of
					 Examiners in Optometry.
(s) "New
					 patient" means a patient who has not received a professional service from a
					 provider in the optometrist's practice group within the preceding 3 years and 1
					 day.
(t) "TMOD" means Treatment and
					 Management of Ocular Disease.